Lin, Chang-Ching http://orcid.org/0000-0001-6659-5543
Chang, Tsung-Cheng http://orcid.org/0000-0003-4706-0468
Wang, Yunguan
Guo, Lei
Gao, Yunpeng
Bikorimana, Emmanuel http://orcid.org/0000-0002-1583-0969
Lemoff, Andrew http://orcid.org/0000-0002-4943-0170
Fang, Yisheng V.
Zhang, He
Zhang, Yanfeng
Ye, Dan
Soria-Bretones, Isabel
Servetto, Alberto
Lee, Kyung-min http://orcid.org/0000-0001-8381-2423
Luo, Xuemei
Otto, Joseph J. http://orcid.org/0000-0003-4157-5559
Akamatsu, Hiroaki
Napolitano, Fabiana http://orcid.org/0000-0002-2463-8952
Mani, Ram http://orcid.org/0000-0003-3552-7905
Cescon, David W. http://orcid.org/0000-0002-1080-0998
Xu, Lin http://orcid.org/0000-0001-5815-4457
Xie, Yang http://orcid.org/0000-0001-9456-1762
Mendell, Joshua T. http://orcid.org/0000-0001-8479-2284
Hanker, Ariella B. http://orcid.org/0000-0002-8655-8341
Arteaga, Carlos L. http://orcid.org/0000-0003-0870-9586
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA142543, CA224899, CA098131)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation (DRC-20-001)
Susan G. Komen (SAB1800010)
U.S. Department of Defense (BC 210406)
Cancer Prevention and Research Institute of Texas (RP220309)
Welch Foundation (I-1961-20210327)
Article History
Received: 22 June 2023
Accepted: 29 February 2024
First Online: 13 March 2024
Competing interests
: J.T.M. is a scientific advisor for Ribometrix, Inc., and owns equity in Orbital Therapeutics, Inc. H.A. receives honoraria from Boehringer Ingelheim Japan Inc., Eli Lilly Japan K.K., and Taiho Pharmaceuticals. A.B.H. received or has received research grants from Takeda and Lilly and nonfinancial support from Puma Biotechnology and Daiichi Sankyo. C.L.A. receives or has received research grants from Pfizer, Lilly, and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation. D.W.C. reports advisory services to AstraZeneca, Exact Sciences, Eisai, Gilead, GlaxoSmithKline, Inivata, Merck, Novartis, Pfizer, and Roche; reports research funding (to institution) from AstraZeneca, Gilead, GlaxoSmithKline, Inivata, Merck, Pfizer, and Roche; and is a member of a trial steering committee for AstraZeneca, Merck, and GlaxoSmithKline. Other authors declare no competing interests.